SECOND QUARTER 2011 EARNINGS CALL July 27 2011 July 27, 2011 - - PDF document

▶
second quarter 2011 earnings call
SMART_READER_LITE
LIVE PREVIEW

SECOND QUARTER 2011 EARNINGS CALL July 27 2011 July 27, 2011 - - PDF document

Apr 18, 2023 278 likes •446 views

1 SECOND QUARTER 2011 EARNINGS CALL July 27 2011 July 27, 2011 FORWARD-LOOKING STATEMENTS Some of the statements made in the presentation whether written or Some of the statements made in the presentation whether written or oral may be

slide-1
SLIDE 1

SECOND QUARTER 2011 EARNINGS CALL

July 27 2011

1

July 27, 2011

slide-2
SLIDE 2

Some of the statements made in the presentation whether written or

FORWARD-LOOKING STATEMENTS

Some of the statements made in the presentation whether written or

  • ral may be “forward-looking statements” within the meaning of Section

27A of the Securities Act of 1933, as amended, and Section 21E of Securities Exchange Act of 1934, as amended, and involve a number

  • f risks and uncertainties. These statements can be identified by

terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are based on the company’s current

  • expectations. The company’s actual results could differ materially from

those stated or implied in such forward looking statements The those stated or implied in such forward-looking statements. The company assumes no

  • bligations

to update forward-looking information, including information in this presentation, to reflect changed assumptions the occurrence of unanticipated events or

2

changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects.

slide-3
SLIDE 3

EARNINGS CALL PARTICIPANTS

› Thomas J Hook › Thomas J. Hook

  • President & CEO

› Thomas J. Mazza

  • Senior Vice President & CFO

› Marco F. Benedetti

C t C t ll & T

  • Corporate Controller & Treasurer

3

slide-4
SLIDE 4

AGENDA

› Second Quarter 2011 Review – Tom Hook › Second Quarter 2011 Review – Tom Hook

  • Financial Highlights
  • Strategic Initiatives Update

g p

› Second Quarter 2011 Financial Results - Tom Mazza

  • Financial Results
  • Guidance

› Question & Answer

4

slide-5
SLIDE 5

SECOND QUARTER 2011 FINANCIAL HIGHLIGHTS

› Sales of $146 5 Million › Sales of $146.5 Million

  • 4% increase over the prior year (1% constant currency)
  • 24% Orthopaedic growth (8% constant currency)

p g ( y)

  • Maintained CRM revenue despite declining market
  • Vascular Access & Electrochem tough comparables

› Operating Results

  • 8% increase in adjusted EPS
  • Driving operational and financial leverage
  • Continued RD&E investment

5

slide-6
SLIDE 6

STRATEGIC INITIATIVES UPDATE

› Grow & Diversify Revenue › Grow & Diversify Revenue

  • Diversified revenue offsetting contracting CRM market
  • Investments in Orthopaedic operations driving market

share gains

  • Establishing long-term agreements in Electrochem

M di l d i t t b d d t tf li d

  • Medical device strategy broadens product portfolio and

deepens customer relationships

6

slide-7
SLIDE 7

STRATEGIC INITIATIVES UPDATE

› Drive Operating Performance

  • Adjusted operating income 12.6% of sales
  • Strong cash generation
  • Strong cash generation
  • Renegotiated revolving credit facility to provide

increased financial flexibility

7

slide-8
SLIDE 8

STRATEGIC INITIATIVES UPDATE

› Deliver Innovative Solutions › Deliver Innovative Solutions

  • Medical device strategy continues to build momentum
  • Sales of new medical devices over $1 million for 1H11
  • 3 medical device distribution agreements signed in 2Q11
  • 27 medical device patents filed in 1H11 (4 granted)
  • In total 48 medical device patents pending (10 granted)
  • 2 medical device regulatory submissions made in 2Q11
  • 3 medical device regulatory approvals received in 2Q11
  • 3 medical device regulatory approvals received in 2Q11

8

slide-9
SLIDE 9

SECOND QUARTER 2011 SALES

› CRM & Neuromodulation revenue

includes benefit of inventory builds &

› Tough comparable vs. 2Q’10

C ti d t th i & includes benefit of inventory builds & product launches

› Vascular Access tough comparable vs.

2Q’10

› Continued strength in energy &

environmental markets

› Expect 2H’11 to be below 1H’11 run-rate › Continue to develop industry leading › 24% Orthopaedic growth (8% cc)

  • Customer product launches
  • Expanded capabilities enabling

market share gains p y g technology for Energy & Portable Medical customers

› Secured long-term supply agreements

9

market share gains

slide-10
SLIDE 10

SECOND QUARTER 2011 FINANCIAL RESULTS

10 10

slide-11
SLIDE 11

FINANCIAL GUIDANCE

› 2011 annual guidance ranges revised as follows: › 2011 annual guidance ranges revised as follows:

Previous Revised Revenue (in millions) $540 - $560 $550 - $570 Adjusted OI as % of Sales* 12% - 13% 12% - 13% Adjusted EPS* $1.55 - $1.65 $1.60 - $1.70

* Excludes non-recurring, unusual or infrequently occurring items such as consolidation and integration charges, certain R&D expenditures, asset disposition and write-down charges. See appendix for reconciling items to GAAP

11 11

GAAP.

slide-12
SLIDE 12

APPENDIX

12 12

slide-13
SLIDE 13

GAAP RECONCILIATION

13 13

slide-14
SLIDE 14

GAAP RECONCILIATION

14 14

slide-15
SLIDE 15

CONTACT INFORMATION

M F B d tti Marco F. Benedetti Corporate Controller & Treasurer G tb t h Greatbatch 10000 Wehrle Drive Clarence, NY 14031 T l 716 759 5856 Tel 716-759-5856 mbenedetti@greatbatch.com www.greatbatch.com

15 15